An observational study in Obesity, Morbid, sponsored by Norwegian University of Science and Technology. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Norwegian University of Science and Technology · Observational
Among 33 studies in Obesity, Morbid by Norwegian University of Science and Technology — 21 open to participants now, 21 under way, none of them phase 3. Obesity, Morbid · Norwegian University of Science and Technology.
Among the 33 studies in Obesity, Morbid by Norwegian University of Science and Technology, this one is the 2nd largest by planned enrollment of the 26 observational ones that give a count, is one of 5 that started in 2018, is one of 26 observational ones, reaches primary completion later than 1 of the 20 other live ones, and was the 12th registered.
941 studies on the registry are indexed under Obesity, Morbid; 163 are open to participants now.
Browse Obesity, Morbid studies →21 of the 33 studies in Obesity, Morbid by Norwegian University of Science and Technology are open now, in 1 country. Recruiting first, the newest first:
Norwegian University of Science and Technology · Sites in Norway
Norwegian University of Science and Technology · Sites in Norway
Norwegian University of Science and Technology · Sites in Norway
Norwegian University of Science and Technology · Sites in Norway
Norwegian University of Science and Technology · Sites in Norway
By country, each count listing its studies:
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 5 started in 2018.
This study's planned enrollment of 12 is below the median of 80 across 311 observational studies indexed under Obesity, Morbid.
Median enrollment 43 across the 7 interventional studies, 12 across the 26 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Norwegian University of Science and Technology is the lead sponsor of 495 studies on the registry; 48 are open to participants now.
3 of the studies in Obesity, Morbid by Norwegian University of Science and Technology that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03448783Norwegian University of Science and TechnologyBariatric Surgery and Pharmacokinetics of Apixaban | 2026-12 |
| NCT03440177Norwegian University of Science and TechnologyBariatric Surgery and Pharmacokinetics of Ramipril | 2026-12 |
| NCT03449485Norwegian University of Science and TechnologyBariatric Surgery and Pharmacokinetics of Chlorprothixene | 2026-12 |
Among the 33 studies in Obesity, Morbid by Norwegian University of Science and Technology, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on quetiapine are investigated.
Patients referred for bariatric surgery (gastric bypass or sleeve gastrectomy)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients are tested for their normal prescription quetiapine medication
Also known as: Quetiapine fumarate
Quetiapine concentration in blood serum (area under curve (AUC))
Time frame: From baseline to 1 year postoperatively
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2018 (actual). Primary completion is estimated for Oct 2026, 105 months after the start.
Of 137 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 105 months is above that.
Counting every sponsor, half of 138 studies reached it within 46 months; a quarter within 16 and three quarters within 132.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norwegian University of Science and Technology →